The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index; 82 of the 214 sources its claims cite were checked for support.
GLP-1 and the Neurobiology of Eating Control: Recent Advances
Open accessAbstract
Obesity is now considered a chronic relapsing progressive disease, associated with increased all-cause mortality that scales with body weight, affecting more than 1 billion people worldwide. Excess body fat is strongly associated with excess energy intake, and most successful anti-obesity medications (AOMs) counter this positive energy balance through the suppression of eating to drive weight loss. Historically, AOMs have been characterized by modest weight loss and side effects which are compliance-limiting, and in some cases life-threatening. However, the field of obesity pharmacotherapy has now entered a new era of AOMs based on analogues of the gut hormone and neuropeptide glucagon-like peptide-1 (GLP-1). The latest versions of these drugs elicit unprecedented levels of weight loss in clinical trials, which are now starting to be substantiated in real-world usage. Notably, these drugs reduce weight primarily by reducing energy intake, via activation of the GLP-1 receptor on multiple sites of action primarily in the central nervous system, although the most relevant sites of action, and the neural circuits recruited remain contentious. Here we provide a targeted synthesis of recent developments in the field of GLP-1 neurobiology, highlighting studies which have advanced our understanding of how GLP-1 signaling modulates eating, and identify open questions and future challenges we believe still need to be addressed to aid the prevention and/or treatment of obesity.
Overview
CoChat Summary
TL;DR
This review synthesizes recent advances in GLP-1 neurobiology and obesity pharmacotherapy, arguing that GLP-1-based anti-obesity medications reduce eating mainly through CNS GLP-1R populations while endogenous peripheral and central GLP-1 systems are functionally separable. It highlights unresolved questions about the sites of action, nausea versus satiety circuits, real-world efficacy, and weight regain.
Key findings
- GLP-1-based AOMs reduce weight primarily by lowering energy intake via GLP-1R activation, mainly in the CNS; semaglutide achieved up to 15% weight loss in trials, while tirzepatide and retatrutide achieved placebo-subtracted weight loss of ≥20%, and CagriSema ∼15% in shorter-term phase 1/2 trials.
- Endogenous gut-derived GLP-1 contributes to satiation mainly through peripheral vagal afferents in the hepatic portal vein and intestinal mucosa, and via the ileal brake circuit; central NTS preproglucagon neurons mediate physiological satiation and stress-induced hypophagia but are not required for liraglutide or semaglutide anorectic effects.
- Recent rodent studies implicate multiple CNS GLP-1R populations in GLP-1RA effects, including the area postrema/NTS, locus coeruleus, hypothalamic arcuate and dorsomedial nuclei, and lateral septum; area postrema GLP-1R neurons may drive nausea, whereas NTS populations may mediate satiety, and tirzepatide’s lower discontinuation-inducing GI events may involve GIPR-expressing GABAergic area postrema neurons.
- Clinical limitations remain: real-world semaglutide weight loss ranges from 4% to 5% in one study to 13.4% in another; SELECT reported 8.7% placebo-subtracted weight loss at 4 years versus 12.5% in STEP 1 at 68 weeks; 10% to 15% of STEP/SURMOUNT participants were nonresponders, 32% in SELECT, and 19% in a real-world setting; GI side effects affect 50% to 60%, with discontinuation in 4% to 10%, and 50% to 65% of lost weight is regained up to a year after semaglutide or tirzepatide cessation.
Methods
- Targeted narrative synthesis of recent developments in GLP-1 neurobiology relevant to obesity, highlighting studies on how GLP-1 signaling modulates eating and identifying open questions for GLP-1-based AOMs.
- Includes discussion of rodent mechanistic studies and a table summarizing key body weight loss efficacy from clinical trials versus real-world studies of GLP-1RAs licensed for obesity.
- No primary experimental data, systematic search strategy, or meta-analytic methods are reported.
Limitations
- The paper states that the most relevant sites of action and neural circuits recruited by GLP-1RAs remain contentious, and that many mechanistic insights come from rodent studies.
- It notes that real-world effectiveness data are conflicting and that clinical trials tend to overestimate weight loss, with limited long-term data for newer GLP-1RA-based combination therapies.
- Evident from the text: as a narrative review, it does not report a systematic search strategy or formal risk-of-bias assessment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
29 Valid · 5 Not valid · 59 Not checked · 10 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Local injection of GLP-1 and/or GLP-1R agonists (GLP-1RAs) elicits anorectic effects in virtually all GLP-1R-expressing CNS regions investigated (reviewed in (15, 16)).”
§ GLP-1 and the Neurobiology of Eating Control: Recent Advances > GLP-1 Systems and the Neurobiology of Obesity > Central GLP-1 System Targets of Endogenous GLP-1 and GLP-1RA Anti-Obesity Medications
What the sources say
- Partly supportedcites [15] McLean, 2021, Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation, Endocr Rev sourceExperimental — accuracy not yet measured
The review reports that intracerebroventricular GLP-1 injection causes hypophagia (GLP-1 receptors within the nervous system, p. 26) and discusses anorectic effects involving particular CNS regions, including the ARC (GLP-1Rs in circumventricular organs, p. 29). It does not establish that local injections elicit anorectic effects in virtually all GLP-1R-expressing CNS regions investigated. (LLM, conf=0.82)
- Disputedcites [16] Trapp, 2022, Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment, Br J Pharmacol sourceExperimental — accuracy not yet measured
The review reports that direct CNS injection of GLP-1 or its receptor agonists can reduce food intake. But in “What are the roles of brain-derived GLP-1,” it emphasizes region-specific effects: GLP-1 microinjection into the central amygdala elicited conditioned taste aversion, not hypophagia. That finding runs against the claim that local injection is anorectic in virtually all investigated regions. (LLM, conf=0.83)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The density of L-cells increases toward the distal end of the gastrointestinal tract, peaking in the ileum and colon—a paradoxical observation given that nutrient-sensing cell density would be expected to be highest in the proximal intestine where nutrient absorption primarily takes place (25, 33).”
§ GLP-1 and the Neurobiology of Eating Control: Recent Advances > GLP-1 Systems and the Neurobiology of Obesity > Endogenous GLP-1 in the Physiological Control of Eating
What the sources say
- Not checked yetcites [25] Gribble, 2021, Metabolic messengers: glucagon-like peptide 1, Nat Metab source
- Supportedcites [33] Lewis, 2020, Selective stimulation of colonic L cells improves metabolic outcomes in mice, Diabetologia source
The Introduction (p.1 of our copy) states that GLP-1 is produced 'alongside another proglucagon product GLP-2 in increasing amounts in the distal gut, where it is co-stored and released with... Peptide YY (PYY)', and that 'the distal gut harbours the majority of endogenous GLP-1 and PYY stores and recruiting this L-cell population could be developed as a therapeutic strategy'. The same Introduction uses 'distal gut' for the ileum and colon ('When Gcg was deleted only from the ileum and colon... suggesting a greater contribution of the distal gut'), so the caudal gradient peaking in ileum/colon is what our copy conveys. The source frames it as hormone content/L-cell population in mice rather than a counted cell density, and the adjacent passage ('As most nutrient absorption occurs in the proximal small intestine...') supplies the paradox framing the citing sentence adds. (LLM, conf=0.80)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interestingly, rather than acting via the canonical mechanosensory VAN pathway (23), ileal GLP-1-evoked gastric distension suppressed eating via a spinal afferent pathway to the parasubthalamic nucleus and a brainstem premotor circuit controlling orofacial food rejection behavior.”
§ GLP-1 and the Neurobiology of Eating Control: Recent Advances > GLP-1 Systems and the Neurobiology of Obesity > Endogenous GLP-1 in the Physiological Control of Eating
What the sources say
- Supportedcites [44] Zhang, 2022, An inter-organ neural circuit for appetite suppression, Cell source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Supportedcites [23] Brierley, 2021, Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating, Br J Pharmacol source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This intestinofugal pathway connects GLP-1R-expressing enteric neurons to stomach-innervating sympathetic neurons which inhibit gastric emptying and eating by a potent nitric oxide neuron-mediated increase in gastric distension.”
§ GLP-1 and the Neurobiology of Eating Control: Recent Advances > GLP-1 Systems and the Neurobiology of Obesity > Endogenous GLP-1 in the Physiological Control of Eating
What the sources say
- Supportedcites [44] Zhang, 2022, An inter-organ neural circuit for appetite suppression, Cell source
The RESULTS sections state each element of the attributed circuit: GLP-1R+ ileal myenteric/intestinofugal neurons project to and activate abdominal sympathetic (celiac) ganglia, and IFNs act on the stomach by recruiting stomach-innervating noradrenergic CG neurons (CGNA–Stom) (RESULTS, 'Ileal intestinofugal myenteric neurons express GLP-1R...' and 'Intestinal GLP-1 controls the stomach via abdominal sympathetic ganglia'). CGNA–Stom preferentially and densely target inhibitory Nos1 gastric neurons, whose activation causes marked gastric distension, inhibits gastric contractions and halves eating, while Nos1Stom ablation abolishes GLP-1ii-induced distension and anorexia (RESULTS, 'Intestinal GLP-1 controls appetite and stomach distension via nitric oxide gastric neurons'; 'Chemical activation of nitric oxide gastric neurons mimics intestinal GLP-1'). The DISCUSSION summarises this as ileal GLP-1 causing anorexia and stomach distension via intestinofugal-mediated sympathetic reflexes that activate gastric nitric oxide neurons, and the abstract's ~100% gastric volume enlargement supports 'potent'. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recent mechanistic studies, primarily conducted in rodents, have identified a number of sites of direct action putatively mediating the effects of GLP-1-based AOMs on eating and body weight, including the area postrema and nucleus tractus solitarius (47‐49), locus coeruleus (50), hypothalamic arcuate (51, 52) and dorsomedial nuclei (53), and the lateral septal nucleus (54).”
§ GLP-1 and the Neurobiology of Eating Control: Recent Advances > GLP-1 Systems and the Neurobiology of Obesity > Endogenous GLP-1 in the Physiological Control of Eating
What the sources say
- Supportedcites [47] Huang, 2024, Dissociable hindbrain GLP1R circuits for satiety and aversion, Nature source
The cited sentence attaches this source (refs 47–49) to the area postrema and nucleus tractus solitarius as sites of direct action of GLP-1-based drugs on eating and body weight, and our copy states exactly that: 'Obesity drugs act on hindbrain GLP1R neurons' reports that peripherally-delivered GLP1-based obesity drugs directly target hindbrain DVC neurons and that DVCGLP1R ablation blocked exendin-4 and semaglutide-induced anorexia and semaglutide-induced weight loss in obese mice, highlighting 'the DVC as a critical site of action'. The Abstract and 'In vivo activity in APGLP1R and NTSGLP1R neurons' section further dissociate the two subregions (NTSGLP1R activation drives satiety, APGLP1R activation drives aversion with reduced intake), supporting the paraphrase's 'putative' framing. The other sites listed in the sentence (locus coeruleus, arcuate, dorsomedial hypothalamus, lateral septum) are credited to separate citations (50–54) and are not part of what this source is offered for; our copy does not address LC, DMH or lateral septum, and it actually finds ARC GLP1R neurons dispensable for drug efficacy. (LLM, conf=0.85)
- Partly supportedcites [48] Zhang, 2021, Area postrema cell types that mediate nausea-associated behaviors, Neuron sourceExperimental — accuracy not yet measured
Our copy supports the area postrema as a direct, rodent-established site of GLP-1-agonist action: the Results section 'Area postrema GLP1R neurons condition flavor avoidance to peripheral poisons' shows exendin-4 acts through GLP1R in the caudal brainstem (region-specific knockout/rescue in AP, not vagal GLP1R), and the AP cell atlas documents Glp1r-expressing neuron clusters. But the effect this source attributes to AP GLP1R neurons is nausea-like aversion, not the effects on eating and body weight the citing sentence claims: the same Results passage states 'exendin-4 still decreased food intake in Glp1r-ABLATEAP mice... suggesting that at least partially distinct neural circuits mediate GLP1R-evoked appetite suppression and nausea,' and the Discussion assigns feeding inhibition to GLP1R neurons in several brain regions (crediting Adams et al. 2018, Burmeister et al. 2017, Fortin et al. 2020, Ghosal et al. 2017, Secher et al. 2014) while aversion is 'a more focal brainstem response.' NTS appears only as a site of Glp1r expression/co-recorded neurons, not as a demonstrated site of action for eating or weight. (LLM, conf=0.78)
- Not checked yetcites [49] Fortin, 2020, GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats, Sci Transl Med source
- Supportedcites [50] Fortin, 2023, The locus coeruleus contributes to the anorectic, nausea, and autonomic physiological effects of glucagon-like peptide-1, Sci Adv source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Supportedcites [51] Secher, 2014, The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss, J Clin Invest source
The Discussion states that peripherally injected liraglutide targets hypothalamic GLP-1Rs on ARC neurons, which bind and internalize the drug, respond electrophysiologically to GLP-1, and whose local GLP-1R blockade attenuates liraglutide-induced weight loss (Discussion, p. n/a). The Introduction/abstract confirms the rodent (rat and mouse) mechanistic design and that ARC uptake is GLP-1R dependent, while the conclusion attributes the weight-lowering mode of action to direct activation of CART/POMC neurons in the ARC. Thus this paper does identify the hypothalamic arcuate nucleus as a site of direct action putatively mediating a GLP-1-based anti-obesity medication's effects on eating and body weight, exactly the part of the sentence carried by citations 51-52. (LLM, conf=0.90)
- Partly supportedcites [52] Imbernon, 2022, Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions, Cell Metab sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
46 more claims · 12 with their cited sources checked
Create a free account to see all 103 claims and to verify the 132 references still open.
- It may state two separate claims as one. 48
- Probably not a substantial claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been pivotal for obesity treatment, achieving 15–25 % weight loss over 12–24 months”
From Weighing the risk of GLP-1 treatment in older adults: Should we be concerned about sarcopenic obesity? (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Gastrointestinal side effects are typically classed as mild or moderate, and reported to subside in most patients following titration up to maintenance doses (77, 79, 104), although they still lead to permanent discontinuation of treatment in 4% to 10% of participants (77, 79, 95).”
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2×
“The loss of lean body mass is another common side effect of GLP-1RAs, with studies reporting that lean mass loss accounts for ∼ 45% and ∼ 25% of total loss for semaglutide (79, 105) and tirzepatide (98), respectively.”
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Phelps, N. H., Singleton, R. K., Zhou, B., Heap, R. A., Mishra, A., Bennett, J. E., Paciorek, C. J., Lhoste, V. P., Carrillo-Larco, R. M., Stevens, G. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02750-2 · Cited by 2,544 · cited 1×
“…by a transition from underweight to obesity as the most prevalent form of malnutrition in almost all countries, with more than 1 billion people now living with obesity due to the worldwide prevalence doubling in men, tripling in women, and quadrupling in children over the last 30 years (6, 7).”
Body-mass index and mortality among 1.46 million white adults
Berrington de Gonzalez, A., Hartge, P., Cerhan, J. R., Flint, A. J., Hannan, L., MacInnis, R. J., Moore, S. C., Tobias, G. S., Anton-Culver, H., Freeman, L. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000367 · Cited by 2,317
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200225 · Cited by 2,164
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Bray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Research works printed but not linked: 2
- Novo Nordisk A/S, Wegovy: Summary of Product Characteristics
- NICE, 2023, Semaglutide for Managing Overweight and Obesity
Cited by
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Salvador, R., Moutinho, C. M. S. G., Sousa, C., Vinha, A. F., Carvalho, M. C., & Matos, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18030399 · Cited by 55
Prokopidis, K., Daly, R. M., & Suetta, C. (2025) · The Journal of nutrition, health and aging · doi:10.1016/j.jnha.2025.100652 · Cited by 40
Type 2 Diabetes and the Multifaceted Gut-X Axes
Guo, H., Pan, L.-T., Wu, Q., Wang, L., Huang, Z., Wang, J., Wang, L., Fang, X., Dong, S., Zhu, Y., et al. (2025) · Nutrients · doi:10.3390/nu17162708 · Cited by 42
Kong, F., Zhao, Y., Zhang, W., Wang, X., Wu, T., Zhou, Z., Xu, Y., Xia, L., & Sun, T. (2026) · Nature Communications · doi:10.1038/s41467-025-67701-9 · Cited by 29
Metadata
- Authors
- Jones, L. A., & Brierley, D. I.
- Affiliations
- University College London (GB)
- Corresponding author
- Brierley, Daniel I
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2025-01-06
- Volume
- 166
- Issue
- 2
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- PMC
- PMC11745901
- OpenAlex
- W4406419586
- Cited by
- 43
- References
- 137
- Citations by year
- 2026: 29 · 2025: 14
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrinology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion, cc-by-nc-nd)
- Funders
- Wellcome Trust (223279/Z/21/Z)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon-like peptide-1, GLP-1 receptor, obesity pharmacotherapy, anti-obesity drugs, food intake regulation, energy intake, central nervous system, neural circuits, gastrointestinal hormones, weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Appetite Regulation, Eating, Humans, Obesity, Signal Transduction, Weight Loss, Anti-Obesity Agents, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 and the Neurobiology of Eating Control: Recent Advances. https://app.cochat.ai/papers/10.1210/endocr/bqae167
- The paper
- Jones, L. A., & Brierley, D. I. (2025). GLP-1 and the Neurobiology of Eating Control: Recent Advances. Endocrinology. https://doi.org/10.1210/endocr/bqae167
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.